- Home
- AMRC vs ELVN Comparison
AMRC vs ELVN Comparison
Compare AMRC & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRC
- ELVN
- Stock Information
- Founded
- AMRC 2000
- ELVN 2016
- Country
- AMRC United States
- ELVN United States
- Employees
- AMRC N/A
- ELVN N/A
- Industry
- AMRC Engineering & Construction
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- AMRC Consumer Discretionary
- ELVN Health Care
- Exchange
- AMRC Nasdaq
- ELVN Nasdaq
- Market Cap
- AMRC 1.2B
- ELVN 1.2B
- IPO Year
- AMRC 2010
- ELVN 2020
- Fundamental
- Price
- AMRC $24.35
- ELVN $20.85
- Analyst Decision
- AMRC Buy
- ELVN Strong Buy
- Analyst Count
- AMRC 7
- ELVN 5
- Target Price
- AMRC $18.57
- ELVN $41.20
- AVG Volume (30 Days)
- AMRC 804.4K
- ELVN 358.6K
- Earning Date
- AMRC 08-04-2025
- ELVN 08-13-2025
- Dividend Yield
- AMRC N/A
- ELVN N/A
- EPS Growth
- AMRC 9.21
- ELVN N/A
- EPS
- AMRC 1.17
- ELVN N/A
- Revenue
- AMRC $1,858,653,000.00
- ELVN N/A
- Revenue This Year
- AMRC $8.59
- ELVN N/A
- Revenue Next Year
- AMRC $9.78
- ELVN N/A
- P/E Ratio
- AMRC $20.79
- ELVN N/A
- Revenue Growth
- AMRC 22.85
- ELVN N/A
- 52 Week Low
- AMRC $8.49
- ELVN $13.30
- 52 Week High
- AMRC $39.68
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- AMRC 67.79
- ELVN 56.87
- Support Level
- AMRC $22.04
- ELVN $19.30
- Resistance Level
- AMRC $22.99
- ELVN $21.01
- Average True Range (ATR)
- AMRC 1.73
- ELVN 1.27
- MACD
- AMRC 0.30
- ELVN 0.21
- Stochastic Oscillator
- AMRC 87.88
- ELVN 86.37
About AMRC Ameresco Inc.
Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.